TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

Serial Number 97769288
602

Registration Progress

Application Filed
Jan 26, 2023
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES
Previous Owner: Replimune Limited
Classes: 005, 042

Trademark Image

TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

Basic Information

Serial Number
97769288
Filing Date
January 26, 2023
Abandonment Date
February 5, 2024
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Feb 16, 2024
Classes
005 042

Rights Holder

Replimune Limited

99
Address
69 Innovation Drive, Milton Park
Abingdon, Oxfordshire OX144RQ
GB

Ownership History

Replimune Limited

Original Applicant
99
Abingdon, Oxfordshire GB

Legal Representation

Attorney
Melanie Howard

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

8 events
Date Code Type Description Documents
Feb 16, 2024 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Feb 16, 2024 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Nov 2, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 2, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Nov 2, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 24, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 15, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 30, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations; viruses; viruses for the treatment of disease; viruses for the treatment of cancer; viruses for inducing immune response; pharmaceuticals; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response; vaccines; immunotherapy products; gene therapy products; Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaid
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 042